TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Alx Oncology Holdings Inc.
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

ALX Oncology reported impressive results from a Phase 2 trial combining evorpacept with rituximab and lenalidomide in treating indolent non-Hodgkin lymphoma, achieving a 92% complete response rate and 100% overall response rate.

Insights
ALXO   positive

Demonstrated strong clinical trial results with high complete response rates, promising efficacy of their lead therapeutic candidate evorpacept, and positive outlook for future development